Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Natera Community
NasdaqGS:NTRA Community
1
Narratives
written by author
0
Comments
on narratives written by author
27
Fair Values set
on narratives written by author
Create a narrative
Natera
Popular
Undervalued
Overvalued
Community Investing Ideas
Natera
AN
AnalystConsensusTarget
Consensus Narrative from 20 Analysts
Signatera, Prospera And Renasight Will Transform Diagnostics
Key Takeaways Strong revenue growth driven by increased diagnostic volumes and strategic partnerships positively impacts Natera's earnings and future revenue potential. Expansion into new health segments with products like Prospera and Renasight could improve gross and net margins through strategic diversification and reimbursement increases.
View narrative
US$191.67
FV
17.9% undervalued
intrinsic discount
14.53%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Your Valuation for
NTRA
NTRA
Natera
Your Fair Value
US$
Current Price
US$157.29
162.2% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-546m
3b
2015
2018
2021
2024
2025
2027
2030
Revenue US$3.3b
Earnings US$648.9m
Advanced
Set Fair Value